Anonymous ID: 195183 July 18, 2021, 7:59 p.m. No.14152149   🗄️.is 🔗kun   >>2177 >>2183 >>2189 >>2192 >>2210 >>2317 >>2396 >>2413 >>2628 >>2649 >>2654

>>14152120

 

I have a good friend. He's actually the one who kinda red-pilled me several years ago. Lives in Canada.

Got the jab.

Now he's like… whatever. We're all gonna have to get it anyway. And I want to travel this fall so… what can I do?

 

I am now seriously wondering if that shot messed with his way of thinking. He's so apathetic about all of it now and like I said, he was the one who got me into this stuff.

Anonymous ID: 195183 July 18, 2021, 8:40 p.m. No.14152394   🗄️.is 🔗kun

>>14152379

NOTABLE

 

Taken together, the novel drug candidate BH-103 appears to be effective in repairing SA loss through the use of a unique mechanism of action to modify the virus receptor. Through this mechanism, BH-103 is capable of reducing binding affinity, while simultaneously remaining stable under neutral environmental conditions. These findings suggest that this formulation may be developed into a useful drug to prevent and treat disease caused by COVID-19-related antibodies.

 

Furthermore, the MOA of BH-103 may have a broad spectrum of efficacy, as it acts on all viruses that share this receptor and is not easily blocked by escape mutations. In addition, BH-103 appears to reduce multiple symptoms traceable to ADAA, including cytokine storm in the acute phase and long-haul symptoms in the later phase of convalescence. Vaccine-related adverse effects and autoimmune manifestations related to COVID-19 are also addressed.

 

The safety of BH-103 appears to be established in animal models. This compound is also easily scalable on a commercial basis, as it is associated with a simple and rapid manufacturing process.